Department of Cardiology, Columbia University Irving Medical Center, New York, New York, USA; Cardiovascular Research Foundation, New York, New York, USA.
Department of Cardiology, Columbia University Irving Medical Center, New York, New York, USA.
J Am Coll Cardiol. 2023 Oct 24;82(17):1711-1735. doi: 10.1016/j.jacc.2023.08.008. Epub 2023 Oct 4.
Interest in the pathophysiology, etiology, management, and outcomes of patients with tricuspid regurgitation (TR) has grown in the wake of multiple natural history studies showing progressively worse outcomes associated with increasing TR severity, even after adjusting for multiple comorbidities. Historically, isolated tricuspid valve surgery has been associated with high in-hospital mortality rates, leading to the development of transcatheter treatment options. The aim of this first Tricuspid Valve Academic Research Consortium document is to standardize definitions of disease etiology and severity, as well as endpoints for trials that aim to address the gaps in our knowledge related to identification and management of patients with TR. Standardizing endpoints for trials should provide consistency and enable meaningful comparisons between clinical trials. A second Tricuspid Valve Academic Research Consortium document will focus on further defining trial endpoints and will discuss trial design options.
人们对三尖瓣反流（TR）患者的病理生理学、病因、管理和结局越来越感兴趣，这是因为多项自然病史研究表明，即使在调整了多种合并症后，TR 严重程度的增加与预后逐渐恶化相关。过去，单纯的三尖瓣手术与高住院死亡率相关，因此开发了经导管治疗方法。第一份三尖瓣瓣膜学术研究联合会文件旨在使疾病病因和严重程度的定义以及旨在解决我们在识别和管理 TR 患者方面的知识差距的试验终点标准化。临床试验终点的标准化应提供一致性，并使临床试验之间能够进行有意义的比较。第二份三尖瓣瓣膜学术研究联合会文件将重点进一步定义试验终点，并讨论试验设计方案。
